The potential role of Id1 in COX-2 mediated angiogenesis in gastric cancer

National Medical Journal of China

Volumn 87, Issue 22, 2007, Pages 1570-1575

  Lei, Ting ^a   Han, Shuang ^b   Guo, Xue Yan ^b   Ding, Rui ^b   Li, Ying ^b   Xie, Hua Hong ^b   Bai, Fei Hu ^b   Wu, Kai Chun ^b   Ding, Jie ^b  

^a Urumqi Stomatological Affiliated Hospital   (China)

^b NONE

Author keywords

Angiogenesis; Epoxy compounds; Stomach neoplasms

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLOOXYGENASE 2; INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CAPILLARY DENSITY; CELL PROLIFERATION; CELL SUSPENSION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STOMACH CARCINOGENESIS; SUPERNATANT; TUMOR VASCULARIZATION; UMBILICAL VEIN; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548242692     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Arbiaer JL. Implications of Epstein-Barr virus (EBV)-induced carcinogenesis on cutaneous inflammation and carcinogenesis: evidence of recurring patterns of angiogenesis and signal transduction. Invest Dermatol, 2005,124: 11-12.
2. Yoshiji H, Noguchi R, Kuriyama S, et al. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol Rep, 2005, 13: 491-495.
3. Chinese source.
4. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem, 2001, 276:18563-18569.
5. Singh B, Berry JA, Shoher A, et al. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol, 2005, 26: 1393-1399.
6. Eibl G, Takata Y, Boros LG, et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res, 2005, 65: 982-990.
7. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat, 1995,36:169-180.
8. Mohammed NA, Abd El-Aleem SA, El-Hafiz HA, et al. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. Clin Pathol, 2004,57: 350-354.
9. Hoper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lunp via cAMP. Am J Respir Cell Mol Biol, 1997,17:748-756.
10. Jiang H, Weyrich AS, Zimmerman GA, et al. Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E2 production that modulate motility. Biol Chem, 2004, 279: 55905-55913.
11. Krysan K, Dalwadi H, Sharma S, et al. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Research, 2004, 64: 6359-6362.
12. Huang SP, Wu MS, Shun CT, et al. Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. Biomed Sci, 2005, 12: 229-241.
13. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. Journal of Cell Science, 2000, 113:3897-3905.
14. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature, 1999, 401: 670-677.
15. Volpert OV, Pili R, Sikder HA, et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell, 2002,10:473-483.
16. Ling MT, Lau TC, Zhou C, et al. Overexpression of Id1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis, 2005, 26: 1668-1676.
17. Sakurai D, Tsuchiya N, Yamaguchi A, et al. Crucial role of inhibitor of DNA binding/differentiation in the vasular endothelial growth factor-induced activation and angiogenic processes of human endothelial cells. J Immunol, 2004,173:5801-5809.
18. Cheung RW, Ling MT, Tsao SW, et al. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis, 2004,25:881-887.
19. Chinese source.
20. Han S, Gou C, Hong L, et al. Expression and significances of Id1 helix-loop-helix protein overexpression in gastric cancer. Cancer Lett, 2004, 216: 63-71.
21. Du GJ, Lin HH, Xu QT, et al. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascular Pharmacol, 2005,43: 112-119.
22. Wang J, Wu K, Bai F, et al. Celecoxib could reverse the hypoxia-induced angiopoietin-2 upregulation in gastric cancer. Cancer Letters, 2005,11:1-8.